First patients to receive new 'Smart Bomb' cancer drug in groundbreaking trial
NCT ID NCT07085091
Summary
This is the first study in people to test a new experimental cancer drug called ALX2004. It aims to find a safe dose and see if the drug can help control advanced cancers that have spread and stopped responding to other treatments. The trial will enroll about 170 adults with specific advanced solid tumors, including lung, head and neck, esophageal, and colorectal cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ALX Center 1
RECRUITINGSpokane, Washington, 99208, United States
-
ALX Center 2
RECRUITINGFairfax, Virginia, 22031, United States
-
ALX Center 3
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
ALX Center 4
RECRUITINGWest Valley City, Utah, 84119, United States
-
ALX Center 5
RECRUITINGHouston, Texas, 77030, United States
-
ALX Center 6
RECRUITINGPortland, Oregon, 97213, United States
-
ALX Center 7
RECRUITINGTampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.